tion has been invited to a news-item published in the 'National Herald' of June 15, 1992, captioned "Bleak future for N-Power industry";

(b) if so, whether there is any shift in Government's policy regarding N-Power; and

(c) what was the proposed allocation for Nuclear Power during the Eighth Five Year Plan, and what is the actual allocation made for this sector during the Plan?

THE MINISTER OF STATE IN THE MINISTRY OF SCIENCE AND TECHNOLOGY, DEPARTMENT OF ELECTRONICS AND DEPARTMENT OF OCEAN DEVELOPMENT AND MINISTER OF STATE IN THE MINISTRY OF PARLIAMENTARY AFFAIRS (SHRI P. KUMARAMANGALAM): (a) Yes, Sir.

(b) There has been no shift in the Government's policy regarding nuclear power. However, the 10,000 MWe programme for the turn of the century has been recast to 5,700 MWe to match the availability of funds.

(c) Against the proposed Eighth Five Year Plan outlay of Rs. 14,400 crores the Planning Commission has indicated a plan outlay of Rs. 4261 crores for nuclear power sector as a whole.

Implementation of Kudankulam Nuclear Power Project

725. SHRI S. K. T. RAMACHANDRAN: Will the PRIME MINISTER be pleased to state:

(a) what are the impediments which delay the construction of Atomic Power Station in Kudankulam, Tamil Nadu;

(b) what steps are being taken by Government to overcome the impediments;

(c) what special efforts are being taken to handle the situation caused by the recent political developments in the erstwhile U.S.S.R.; and

(d) by when this Atomic Power Station is expected to be commissioned?

THE MINISTER OF STATE IN THE MINISTRY OF SCIENCE AND TECHNOLOGY, DEPARTMENT OF ELECTRONICS AND DEPARTMENT OF OCEAN DEVELOPMENT AND MINISTER OF STATE IN THE MINISTRY OF PARLIAMENTARY AFFAIRS (SHRI P. R. KUMARAMANGALAM): (a) Recent political developments in the erstwhile USSR have introduced uncertainties.

(b) and (c) Preliminary discussions have been initiated with the Russian Federation. Through these discussions responsibilities for supply of equipment, credit etc. will have to be re-affirmed.

(d) No completion schedule can be indicated at this stage due to the above factors.

Flouting provisions of DPCO, 1987

726. SHRI RAMACHANDRAN PILLAI: Will the PRIME MINISTER be pleased to state:

(a) what action Government have taken against the drug companies who are more often flouting the provisions of Drug Price Control Order of 1987; and

(b) how many drug companies have been penalised for the above reasons?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) Whenever any instance of violation of DPCO comes to the notice of the Government, the matter is examined and further action is taken as per the provisions of DPCO, 1987 and the Essential Commodities Act.

(b) Certain instances of overcharging in bulk drugs and formulations have come to the notice and these cases are at vairous stages of examination. These cases are listed in the enclosed Statement. (*See* below) Powers for taking action for violation of DPCO are also vested in the State Governments and officers subordinate to it.

Statement

Sl. No.	Name of the Company	Name of the Bulk Drug/Formulation
1	2	3
1	M/s. Sarabhai M. Chemicals	Vitamin C
2	M/s. Warner Hindustan	Isokin
3	M/s. Boehringer Knoll	Euglucon
4	M/s. IDPL	Imported Bulk drugs
5	M/s. A.P. Chemicals	Paracetamol
6	M/s. Malladi Drugs	Ephedrin
7	M/s. Krupa Traders.	Rifampicin
8	M/s. IDPL	Sulphadimidine
9	M/s. Sandoz (I) Ltd.	Multi Vitamins
10	M/s. Pifzer (I) Ltd.	Multi Vitamins
11	M/s. Lupin Labs.	Rifampicin, Ethambutol and Pyrazinamide
12	M/s. Carews Pharmaceuticals	Combiflam
13	M/s. Bharat Chemicals	Paracetamol
14	M/s. I.R. Enterprises	Paracetamol
15	M/s. Star Enterprises.	Paracetamol
16	M/s. Shri Paras Pharmaceuticals	Paracetamol
17	M/s. Likhis Chemicals	Trimethoprim
18	M/s. Merind	Dexamethasone
19	M/s. Novacare Pvt. Ltd.	Megadol Tablets
20	M/s. Celsus Pharmaceutical	Iboxes Capsules
21	M/s. Ultim Pharmaceuticals	Proxyvon Capsules
22	M/s. Lyka Lab.	Flucort Range of formulations
23	M/s. Carews Pharmaceuticals	Combiflame Tablets
24	M/s. Infar (I) Ltd.	Dexona Topic
25	M/s. Danis Pharmacy	Flagyl Injection

1	2	3
26	M/s. Ranbaxy Labs.	Brustan Tablets etc.
27	M/s. Cadila Labs.	Dexona E/E Drops
28	M/s. Albert David (I) Ltd.	Analflam Tabs.
29	M/s. Rhone Poulenc (I) Ltd.	Avomine

महाराष्ट्र में गैस आधारित उर्वरक एकक का स्थापित किया जाना

727. **श्री विश्वास रामराव पाटिल** : क्या प्रधान मंत्री यह बताने की कृपा करेंगे कि :

(क) क्या महाराष्ट्र में गैस पर आधारित एक उवर्रक एकक स्थापित किए जाने का कोई प्रस्ताव सरकार के विचाराधीन है ; और

(ख) यदि हां, तो उसका ब्यौरा क्या है ?

रसायन और उर्वरक मंत्रालय में राज्य मंत्री (श्री चिन्ता मोहन) : (क) और (ख) राष्ट्रीय कैमिकल्स एण्ड फर्टिलाइजर्स लि० (आर.सी.एफ.) ने प्राकृतिक गैस पर आधारित महाराष्ट्र के अपने थाल संयंत्र के विस्तार/रेट्रोफिटिंग के लिए सरकार के समक्ष दो प्रस्ताव किए हैं । प्रथम प्रस्ताव में 250/- करोड रुपए की लागत से 700 टन प्रतिदिन अमोनिया तथा 1200 टन प्रतिदिन यूरिया के अतिरिक्त उत्पादन के लिए वर्तमान अमोनिया और यूरिया संयंत्रों को रेट्रोफिट करना परिकल्पित है । दूसरे प्रस्ताव में 956/- करोड़ रुपए की लागत पर 900 टन प्रतिदिन अमोनिया, 1200 टन प्रतिदिन नाइट्रोफासफेट तथा 1074 टन प्रतिदिन सी ए एन का उत्पादन करने के लिए अतिरिक्त संयंत्र स्थापित करने की परिकल्पना की गई है । चूंकि इन दोनों प्रस्तावों के लिए प्राकृतिक गैस की अतिरिक्त मात्रा की आवश्यकता होगी और अतिरिक्त गैस उपलब्ध होने का अब तक कोई संकेत नहीं है अतः कोई निर्णय नहीं लिया गया है ।

Special quality aspect of drugs

728. SHRI RAJNI RANJAN SAHU: Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 1138 given in Rajya Sabha on 7th may, 1992 and state:

(a) what were the cases involving special quality aspects wherein landed cost of imports being higher than the weighted average of CGHS formed the basis of price fixation of formulations in the last three years, year-wise;

(b) what was the DGHS weighted average price and what was the landed cost of imports on which formulation price were based;

(c) what were the names of companies involved in these cases and who accepted this special quality aspect;

(d) whether it is a fact that his Ministry is also introducing the aspect of special quality in the indigenously produced bulk drugs; and

(e) if so, by when and what are the details thereof?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) to (c) There is only one case in recent times involving the special quality aspects where the landed cost of imports adopted in the pricing of formulation was higher than the DGHS weighted average. Necessary details are given as under: